Bausch & Lomb v. Dr. Reddy’s: Prostaglandin Patent Dispute Ends in Settlement
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Bausch & Lomb, Inc., et al. v. Dr. Reddy’s Laboratories, Ltd., et al. |
| Case Number | 3:23-cv-03463 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Jun 2023 – Jun 2025 2 years (734 days) |
| Outcome | Dismissed Without Prejudice |
| Patents at Issue | |
| Accused Products | Prostaglandin Derivatives |
Case Overview
The Parties
⚖️ Plaintiff
Global ophthalmic pharmaceutical and medical device company, co-plaintiffs include Bausch & Lomb Ireland Limited and Nicox S.A.
🛡️ Defendant
Leading generic pharmaceutical manufacturer with a history of ANDA filings.
Patents at Issue
This landmark case involved four U.S. patents covering prostaglandin derivative compounds, a commercially significant class of molecules used in ophthalmic therapeutics:
- • US8058467B2 — Prostaglandin derivatives for ophthalmic use
- • US7273946B2 — Prostaglandin derivatives for ophthalmic use
- • US7629345B2 — Prostaglandin derivatives for ophthalmic use
- • US7910767B2 — Prostaglandin derivatives for ophthalmic use
Developing a new pharmaceutical compound?
Check if your formulation might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
The case was **dismissed without prejudice** on June 30, 2025, after the parties reached a private settlement. No damages were awarded, and no judicial finding on patent validity or infringement was issued.
Key Legal Issues
The dispute centered on the validity and infringement of four patents related to prostaglandin derivative compounds, a crucial class of molecules in ophthalmic therapeutics. The case resolved before a Markman hearing or summary judgment ruling, leaving claim construction unaddressed by the court.
Filing a pharmaceutical patent?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in ophthalmic drug development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation in the prostaglandin space.
- View the 4 asserted patents and their claims
- Analyze prosecution history for validity insights
- Understand common claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical compound or formulation.
- Input your compound structure or formulation details
- AI identifies potentially blocking patents in ophthalmic drug class
- Get actionable risk assessment report
High Risk Area
Prostaglandin derivative compounds
4 Asserted Patents
In prostaglandin derivative class
Settlement Outcome
Implies perceived patent strength
✅ Key Takeaways
For Patent Attorneys & Litigators
Multi-patent pharmaceutical assertions in NJ District Court remain an effective litigation strategy for branded companies.
Search related case law →Dismissal without prejudice with jurisdiction retention preserves enforcement rights under private settlement agreements.
Explore precedents →Absence of a Markman or summary judgment ruling keeps claim scope questions open for future disputes.
Review asserted patent claims →For R&D Teams
Prostaglandin derivative patents remain commercially litigated as of 2025; conduct updated FTO analyses before advancing compounds in this class.
Start FTO analysis for my product →The 734-day litigation duration underscores the cost of inadequate pre-launch patent clearance.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.